首页> 美国卫生研究院文献>Open Forum Infectious Diseases >LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones a European Phase II Randomized Controlled Trial (SHIELD)

【2h】

LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones a European Phase II Randomized Controlled Trial (SHIELD)

机译：LB-5。 Dav132保护用喹诺酮类药物治疗的患者的肠道微生物欧洲II期随机对照试验（盾牌）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Antibiotics elicit intestinal dysbiosis with short and long-term deleterious effects. A colon-targeted adsorbent, DAV132, prevents dysbiosis in healthy humans and may protect antibiotic-treated patients.

机译：抗生素引发肠道消化不良，短期和长期有害效果。结肠靶向的吸附剂DAV132可防止健康人体中的脱敏，并且可以保护抗生素治疗的患者。

著录项

期刊名称 Open Forum Infectious Diseases
作者
Annie Ducher; Maria J G T Vehreschild; Maria J G T Vehreschild; Thomas J Louie; Oliver A Cornely; Céline Féger; Aaron Dane; Aaron Dane; Marina Varastet; Jean de Gunzburg; Antoine Andremont; France Mentré;
展开▼
作者单位

展开▼
年(卷),期 2020(7),Suppl 1
年度 2020
页码 S845–S846
总页数 2
原文格式 PDF
正文语种
中图分类病毒传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial [J] . Dong Yi, Qu Jiazhi, Zhang Zhijun, Neurological Research: An Interdisciplinary Quarterly Journal . 2020,第4期

机译：治疗急性缺血性脑卒中患者的人泌尿基因酶：来自随机双盲安慰剂控制IIB和第III期临床试验的合并数据分析
2. Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial [J] . Kavanaugh Arthur, McInnes Iain B., Krueger Gerald G., Arthritis care & research . 2013,第10期

机译：患者报告的结果和与Golimumab治疗的活性银屑病关节炎患者临床反应的关联：通过2年的III，多中心，随机，双盲，安慰剂对照试验
3. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) [J] . Yoshioka H., Azuma K., Yamamoto N., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第10期

机译：厄洛替尼联合或不联合c-Met抑制剂tivantinib（ARQ 197）的一项随机，双盲，安慰剂对照的III期临床试验，在亚洲患者中曾接受过野生型表皮IIIB / IV期非鳞状非小细胞肺癌的治疗生长因子受体（注意研究）
4. Development of the iPAM MkII system and description of a randomized control trial with acute stroke patients [C] . Jackson A.E., Levesley M.C., Makower S.G., 2013 IEEE 13th International Conference on Rehabilitation Robotics . 2013

机译：iPAM MkII系统的开发以及急性卒中患者的随机对照试验说明
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients [O] . Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, 2020

机译：upadacitinib与Houndbo或Adalimumab与类风湿性关节炎患者的背景甲氨蝶呤和对甲氨蝶呤的反应不足：中欧和东欧患者的III期随机对照试验的亚组分析
7. LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD) [O] . Annie Ducher, Maria J G T Vehreschild, Thomas J Louie, 2020

机译：LB-5。 Dav132保护用喹诺酮类药物治疗的患者的肠道微生物，欧洲II期随机对照试验（盾牌）

LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones a European Phase II Randomized Controlled Trial (SHIELD)

摘要

著录项

相似文献

相关主题

期刊订阅